Neon Therapeutics Inc (NASDAQ:NTGN) was down 11.6% on Monday . The stock traded as low as $2.74 and last traded at $2.89, approximately 640,483 shares changed hands during mid-day trading. An increase of 301% from the average daily volume of 159,603 shares. The stock had previously closed at $3.27.

Several equities research analysts have recently weighed in on NTGN shares. Morgan Stanley reduced their price target on Neon Therapeutics from $19.00 to $13.00 and set an “overweight” rating on the stock in a report on Tuesday, July 16th. Robert W. Baird started coverage on Cue Biopharma in a report on Thursday. They issued an “outperform” rating and a $13.00 price target on the stock. HC Wainwright reiterated a “buy” rating on shares of CytRx in a report on Tuesday, July 16th. Zacks Investment Research upgraded Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Tuesday, July 16th. Finally, Mizuho set a $21.00 price target on Neon Therapeutics and gave the stock a “buy” rating in a report on Monday, July 1st. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $15.13.

The stock has a fifty day simple moving average of $4.33. The stock has a market cap of $92.64 million and a P/E ratio of -0.52. The company has a quick ratio of 7.30, a current ratio of 7.30 and a debt-to-equity ratio of 0.09.

Neon Therapeutics (NASDAQ:NTGN) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.03). As a group, analysts predict that Neon Therapeutics Inc will post -2.69 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp increased its holdings in Neon Therapeutics by 17.6% during the 4th quarter. Bank of New York Mellon Corp now owns 19,427 shares of the company’s stock worth $98,000 after purchasing an additional 2,905 shares during the period. Harel Insurance Investments & Financial Services Ltd. increased its holdings in Neon Therapeutics by 100.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 10,000 shares of the company’s stock worth $65,000 after purchasing an additional 5,000 shares during the period. Bank of America Corp DE increased its holdings in Neon Therapeutics by 42.7% during the 4th quarter. Bank of America Corp DE now owns 21,712 shares of the company’s stock worth $109,000 after purchasing an additional 6,493 shares during the period. Marshall Wace North America L.P. purchased a new position in Neon Therapeutics during the 1st quarter worth $49,000. Finally, Rhumbline Advisers purchased a new position in Neon Therapeutics during the 1st quarter worth $78,000. Institutional investors own 69.53% of the company’s stock.

About Neon Therapeutics (NASDAQ:NTGN)

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Read More: 52-Week High/Low Prices For Stock Selection

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.